Posted by Michael Wonder on 29 Jun 2020
IMC responds to Federal Court decision regarding PMPRB regulatory changes
29 June 2020 - Innovative Medicines Canada released the following statement today in response to the Federal Court of Canada’s decision on its judicial review application regarding the Patented Medicine Prices Review Board amendments to the Patented Medicines Regulations:
“We have just received the Federal Court’s decision and are reviewing it with our members and with counsel to assess its impact.
“We remain deeply concerned about the negative impact the amended Patented Medicines Regulations will have on Canadians’ access to affordable, innovative medicines, and on the country’s ability to attract investment to our life-sciences sector.
